Pancreatic β cell-derived exosomal miR-29 family enhances hepatic glucose output

January 22, 2021

In a new study published in Journal of Extracellular Vesicles, Chen-Yu Zhang's group at Nanjing University, School of Life Sciences, and Antonio Vidal-Puig's group at University of Cambridge report that pancreatic β cells secrete miR-29 family members (miR-29s) via exosomes in response to high levels of free fatty acids (FFAs). Theses β cell-derived exosomal miR-29s regulate glucose homeostasis through their manipulations on glucose output in liver.

Previously, Chen-Yu Zhang's group identified extracellular miRNA as a new form of cell-to-cell communication. They are among the first that reported the selective secretion of miRNAs under different physiological or pathological states; also, the uptake and function of secreted miRNAs in recipient cells. In the past decade, intensive studies have revealed the role of extracellular miRNAs in a range of biological processes. Thus, as a newly-emerged secretory, more insightful studies are need to further reveal its relevance to more physiological progresses and diseases. Pancreatic islet has long been identified as critical secretory tissue in term of its role on maintaining glucose homeostasis by releasing conventional hormones, such as glucagon and insulin. Since pancreatic islet is a classic secretory organ, study to identify its secreted miRNAs and their functional implications in the regulation of glucose homeostasis is very needed.

In the current study, they show that high levels of FFAs can selectively induce the secretion of miR-29s from cultured pancreatic β cells. In vivo study revealed both physiological (fasting)-and pathological (obese)-associated high levels of FFAs induce the secretion of miR-29s from pancreatic β cells. Likewise, miR-29s are also increased in the plasma of obese human compared to normal human. Intriguingly, they discovered that exosomal miR-29s administrated intravenously can cause impaired insulin sensitivity. Next, they used a combination of genetic modification animals to further confirm the functional role of secreted miR-29s. First, mice overexpressed miR-29s in β cells show insulin resistance and an enhanced hepatic glucose output, indicating β cell-derived miR-29s may target liver and impact hepatic insulin action. To confirm this, a distinguishable mutant miR-29a (with four nucleotides mutated in non-seed region) was overexpressed in pancreatic β cells of mice. Consistently, these mice show impaired insulin sensitivity. By tracking the distribution of mutant miR-29a, they found β cell-derived mutant miR-29a can be taken up by liver. Mechanism dissections revealed that β cell-derived miR-29s negatively regulate insulin signalling pathway via targeting p85 α (regulatory subunit of PI3K), and subsequently attenuate the suppression of insulin on glucose output. Finally, miR-29s deficiency in β cell significantly improves the insulin sensitivity in mice fed on HFD. This study not only identifies a new secretory factor from pancreatic β cells, but also elucidates an alternative mechanism that underlies β cell-controlled glucose homeostasis.

This work is important for the following reasons:
  1. We demonstrate pancreatic islets secrete not only canonical hormones, but also exosomal miRNAs, which is largely extended our understanding of islet function;
  2. We identify a new secretory that play a role in regulation of glucose homeostasis.
  3. We reveal a mechanism underlying obesity/FFAs-induced insulin resistance and type 2 diabetes. Obesity or high levels of FFA may not only directly affect liver, skeletal muscle and white adipose tissue and cause insulin resistance, but regulate exogenous secreted miRNA to indirectly result in pathophysiology as well. More importantly, the secreted miR-29s is increased prior to the onset of insulin resistance in ob/ob mice, indicating secreted miR-29s may be the factors that initiate the development of insulin resistance.
  4. We provide further evidence for the selectivity of secreted miRNAs under certain physiological or pathological context.
The researchers of this project include Jing Li, Yujing Zhang, Yangyang Ye, Dameng Li, Yuchen Liu, Eunyoung Lee, Mingliang Zhang, Xin Dai, Xiang Zhang, Shibei Wang, Junfeng Zhang, Weiping Jia, Ke Zen, Antonio Vidal-Puig, Xiaohong Jiang, Chen-Yu Zhang.

This work was supported by grants the National Natural Science Foundation of China (31741066, 31200874, 31771666, 31200969, 81101330, 31271378, 81250044, and 31972912), the National Basic Research Program of China (973 Program) (No. 2011CB504803), the National Key Research and Development Program of China (2017YFC0909700), the Natural Science Foundation of Jiangsu Province, China (BK20130890, BK2011013 and BK2012014), the Fundamental Research Funds for the Central Universities (020814380148, 020514380226), the National Science Fund for Distinguished Young Scholars (81025019) and the programme for New Century Excellent Talents in University from the Ministry of Education, China (NCET-12-0261). Vidal-Puig is funded by MRC-MDU programme grant.

Li et al.: "Pancreatic β cells control glucose homeostasis via the secretion of exosomal miR-29 family" published on Journal of Extracellular Vesicle, 21 January 2021.

Author contact:
Prof. Chen-Yu Zhang
(Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, Chinese Academy of Medical Sciences Research Unit of Extracellular RNA, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute of Life Sciences (NAILS), Institute of Artificial Intelligence Biomedicine, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China)
Tel: +86-25-89680245;

Nanjing University School of Life Sciences

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to